{'fraction_non_alphanumeric': 0.036065573770491806, 'fraction_numerical': 0.006557377049180328, 'mean_word_length': 5.23469387755102, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
CSF p‐Tau/Aβ40 ratio predicts longitudinal hypometabolism and cognitive decline in amyloid‐negative elderly adults

Tauopathy can be measured with PET imaging and CSF phosphorylated tau (p‐Tau), and recent studies have suggested that CSF p‐Tau may be superior to tau PET for detecting early tau increase. We recently found the use of a CSF p‐Tau/Aβ40 ratio improved the associations with Alzheimer’s disease (AD) biomarkers over CSF p‐Tau. However, the significance of elevated CSF p‐Tau in the absence of abnormal Aβ is unclear, as is how it relates to neurodegeneration, cognitive decline, and other factors.